Sign up Australia
Proactive Investors - Run By Investors For Investors

Atlas Iron's shares soar while also being the ASX Volume Leader at noon

Atlas has traded $6 million worth of shares in the first two hours of 2018.
Atlas Iron's shares soar while also being the ASX Volume Leader at noon
The most active stocks on the ASX intra-day

Atlas Iron's (ASX:AGO) shares have soared 16.1% to $0.036 intra-day, with over 170 million changing hands.

The company is by far the most active on the ASX.

Taking a longer view, shares in the company are up 75% over the past two weeks.

Providing the positive re-rating has been Atlas’ diversification strategy which is expected to generate strong free cashflow for a minimal capital outlay.

Under a deal with Pilbara Minerals (ASX:PLS), Atlas will purchase 1 million tonnes to 1.5 million tonnes of lithium DSO from the company over 15 months.

Pilbara Minerals will mine the ore at its Pilgangoora Project with Atlas taking ownership of the ore at the mine gate.

Atlas will process and transport the ore using its existing infrastructure, including its Mt Dove crusher and Utah Point port facilities

First export sales scheduled for June 2018 quarter.

Company Name Code Last Change Volume
Atlas Iron Ltd AGO $0.036 16.13% 167,350,162
First Growth Funds Ltd FGF $0.032 88.24% 138,139,299
Serpentine Technologies Ltd S3R $0.015 15.39% 47,046,058
Zyber Holdings Ltd ZYB $0.020 11.11% 40,517,319
Latin Resources Ltd LRS $0.013 18.18% 39,318,696
Reffind Ltd RFN $0.050 8.70% 35,955,565
Vector Resources Ltd VEC $0.032 3.23% 34,530,112
Winmar Resources Ltd WFE $0.005 25% 27,684,152
Chapmans Ltd CHP $0.012 9.09% 17,930,794
South East Asia Ltd SXI $0.032 14.29% 15,939,478

 

View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

Clint Eastwood
May 25 2018
The group’s first piece of original content, a documentary called Pandas, premiered on 24 March this year, to positive reviews.
Email
Wed
Milan Patel, dotdigital’s chief executive officer said: "This year reflects substantial progress against the company's strategic aims in accelerating our platform capabilities into the omnichannel space, continuing to innovate our product, growing geographically and deepening our relationships with our strategic partners”
Cello
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use